Related references
Note: Only part of the references are listed.Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies
Ana Puda et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Allogeneic Hematopoietic Cell Transplantation for Chronic Myelofibrosis in Australia and New Zealand: Older Recipients Receiving Myeloablative Conditioning at Increased Mortality Risk
Ian Nivison-Smith et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
Joannah Score et al.
BLOOD (2012)
The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation
Bart L. Scott et al.
BLOOD (2012)
JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths
Ayalew Tefferi
BLOOD (2012)
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome
Su-Jiang Zhang et al.
BLOOD (2012)
Circulating CD34+ cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT
H. Alchalby et al.
BONE MARROW TRANSPLANTATION (2012)
The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries
J. Abelsson et al.
BONE MARROW TRANSPLANTATION (2012)
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
A. Tefferi et al.
LEUKEMIA (2012)
Leukemia risk models in primary myelofibrosis: an International Working Group study
A. Tefferi et al.
LEUKEMIA (2012)
One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Ayalew Tefferi et al.
MAYO CLINIC PROCEEDINGS (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis
H. Joachim Deeg et al.
BLOOD (2011)
EZH2 mutational status predicts poor survival in myelofibrosis
Paola Guglielmelli et al.
BLOOD (2011)
Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival
Rakhee Vaidya et al.
BLOOD (2011)
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
Angela G. Fleischman et al.
BLOOD (2011)
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)
Marie Robin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age
Scott Samuelson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Reducing the Risk for Transplantation-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: How Much Progress Has Been Made?
John T. Horan et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients
D. Caramazza et al.
LEUKEMIA (2011)
Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients
A. Pardanani et al.
LEUKEMIA (2011)
DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms
O. Abdel-Wahab et al.
LEUKEMIA (2011)
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients
Alejandra Martinez-Trillos et al.
ANNALS OF HEMATOLOGY (2010)
Outcome of Transplantation for Myelofibrosis
Karen K. Ballen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis
Shinsuke Takagi et al.
BLOOD (2010)
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms
Stephen T. Oh et al.
BLOOD (2010)
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
Jeffrey W. Tyner et al.
BLOOD (2010)
Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis
Francesco Passamonti et al.
BLOOD (2010)
Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
Haefaa Alchalby et al.
BLOOD (2010)
Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type
A. Bacigalupo et al.
BONE MARROW TRANSPLANTATION (2010)
The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study
W. A. Stewart et al.
BONE MARROW TRANSPLANTATION (2010)
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence
Francesco Passamonti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis
Marie Robin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias
Omar Abdel-Wahab et al.
CANCER RESEARCH (2010)
Therapeutic options for patients with myelofibrosis in blast phase
John Mascarenhas et al.
LEUKEMIA RESEARCH (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Defining the Intensity of Conditioning Regimens: Working Definitions
Andrea Bacigalupo et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
CEBPA promoter hypermethylation in a subset of myeloid/T-lymphoid leukemias with a distinct gene expression profile Response
Bas Wouters et al.
BLOOD (2009)
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele
Paola Guglielmelli et al.
BLOOD (2009)
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Nicolaus Kroeger et al.
BLOOD (2009)
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course
Constantine S. Tam et al.
BLOOD (2009)
A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis
V. Gupta et al.
BONE MARROW TRANSPLANTATION (2009)
The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan
Tomonori Hidaka et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Graft-versus-host disease
James L. M. Ferrara et al.
LANCET (2009)
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis
A. Tefferi et al.
LEUKEMIA (2009)
The natural history and treatment outcome of blast phase BCR-ABL(-) myeloproliferative neoplasms
Constantine S. Tam et al.
BLOOD (2008)
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis
Francesco Passamonti et al.
BLOOD (2008)
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
Francesca Patriarca et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival
A. Tefferi et al.
LEUKEMIA (2008)
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis
Giovanni Barosi et al.
BLOOD (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia
Daniella M. B. Kerbauy et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2007)
No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis
Markus Ditschkowski et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Palliative goals, patient selection, and perioperative platelet management - Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic
Ruben A. Mesa et al.
CANCER (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis
D Dingli et al.
CANCER (2006)
V617F mutation in JAK2 is associated idiopathic myelofibrosis
PJ Campbell et al.
BLOOD (2006)
Allogeneic hematopoietic stern-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia
D Rondelli et al.
BLOOD (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases
RA Mesa et al.
BLOOD (2005)
Allogeneic hematopoietic stem cell transplantation for myelofibrosis
HJ Deeg et al.
BLOOD (2003)
Stem cell transplantation for myelofibrosis: a report from two Canadian centers
A Daly et al.
BONE MARROW TRANSPLANTATION (2003)
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia
SM Devine et al.
BLOOD (2002)
Self-renewal of multipotent long-term repopulating hematopoietic stem cells is negatively regulated by Fas and tumor necrosis factor receptor activation
D Bryder et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Tumor necrosis factor (TNF)-mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells
I Dybedal et al.
BLOOD (2001)
Splenectomy and hemopoietic stem cell transplantation for myelofibrosis
ZH Li et al.
BLOOD (2001)
Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect
F Cervantes et al.
BONE MARROW TRANSPLANTATION (2000)
Medical progress: Myelofibrosis with myeloid metaplasia.
A Tefferi
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
